background
background
GLMD
Galmed Pharmaceutica
$1.3200
+0.0600
+4.76%
Earnings Expectation?
Beat
Meet
Miss
Expected Price Action?
Up
Flat
Down
Thursday
April 10, 2025
8:00 AM ET
Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor
Wednesday
April 2, 2025
4:10 PM ET
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024